NCT04796324 - Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

December 1, 2024

Study Completion Date

November 1, 2025

Conditions

Metastatic Breast Cancer

Interventions

DRUG

Ixabepilone Injection

Ixabepilone 40 mg/m2 is administered as a 3-h intravenous infusion Day 1 in a 3-week cycle

Trial Locations (19)

1200

Clin. Univ. Saint-Luc, Brussels

2650

Antwerp University Hospital, Antwerp

3083

Ikazia Hospital Rotterdam, Rotterdam

4000

CHU de Liege, Oncology Department, Liège

9300

Onze-Lieve-Vrouwziekenhuis, Aalst

10117

Charité - Universitätsmedizin Berlin, Berlin

33520

Tampere University Hospital, Tampere

41124

Modena University Hospital, Modena

21-500

Wojewodzki Szpital Specjalietyczny, Biała Podlaska

80-214

Uniwersyteckie Centrum Kliniczne, Gdansk

20-090

Centrum Onkologii Ziemi Lubelskiej im., Lublin

61-848

Oddział Onkologii Klinicznej, Szpital Kliniczny Przemienienia Pańskiego UM w Poznaniu, Poznan

ME7 5NY

Medway NHS Foundation Trust, Gillingham

G12 0YN

Beatson West of Scotland Cancer Centre, Glasgow

TA1 5DA

Somerset NHS Foundation Trust, Taunton

SA2 8QA

Cancer Institute Singleton Hospital, Swansea

EH4 2XR

Edinburgh Cancer Centre, Western General Hospital, Edinburgh

LS9 7TF

St James Hospital, Leeds

NG5 1PB

Nottingham University Hospitals, Nottingham